Is Leap Therapeutics, Inc. overvalued or undervalued?

As of 12 August 2022, Leap Therapeutics, Inc. moved from a grade of risky to does not qualify. The company is currently considered overvalued given its financial metrics and peer comparisons. Key ratios include a Price to Book Value of 0.78, an EV to EBIT of 0.22, and an astonishing ROCE of 626.53%, although the ROE is notably negative at -331.91%.
In comparison to its peers, Leap Therapeutics, Inc. has a less favorable valuation with a peer EV to EBITDA of 0.2332, while companies like Precision BioSciences, Inc. show a more negative EV to EBITDA of -0.1189. The stock has significantly underperformed against the S&P 500, with a year-to-date return of -89.25% compared to the index's 2.44%. Overall, the current valuation suggests that Leap Therapeutics, Inc. is overvalued in the market.